Madrigal

madrigal-pays-$50m-for-pfizer-mash-drug-with-eye-on-rezdiffra-combo-potential

Biotechnology Madrigal Uncategorized

Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential

Jan 9, 2026

Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the...

madrigal-pens-$2b-pact-for-cspc’s-preclinical-glp-1-with-eye-on-rezdiffra-mash-pairing

Biotechnology Madrigal Uncategorized

Madrigal pens $2B pact for CSPC’s preclinical GLP-1 with eye on Rezdiffra MASH pairing

Jul 30, 2025

Madrigal Pharmaceuticals is paying $120 million upfront for a preclinical GLP-1 receptor agonist that the...